ATE510534T1 - Naltrexonhydrochlorid-zusammensetzungen - Google Patents

Naltrexonhydrochlorid-zusammensetzungen

Info

Publication number
ATE510534T1
ATE510534T1 AT03716588T AT03716588T ATE510534T1 AT E510534 T1 ATE510534 T1 AT E510534T1 AT 03716588 T AT03716588 T AT 03716588T AT 03716588 T AT03716588 T AT 03716588T AT E510534 T1 ATE510534 T1 AT E510534T1
Authority
AT
Austria
Prior art keywords
naltrexone hydrochloride
hydrochloride compositions
compositions
naltrexone
stabilizing
Prior art date
Application number
AT03716588T
Other languages
English (en)
Inventor
Benjamin Oshlack
Hua-Pin Huang
Philip Goliber
Richard Mannion
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Application granted granted Critical
Publication of ATE510534T1 publication Critical patent/ATE510534T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
AT03716588T 2002-03-14 2003-03-14 Naltrexonhydrochlorid-zusammensetzungen ATE510534T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36452102P 2002-03-14 2002-03-14
PCT/US2003/007932 WO2003077867A2 (en) 2002-03-14 2003-03-14 Naltrexone hydrochloride compositions

Publications (1)

Publication Number Publication Date
ATE510534T1 true ATE510534T1 (de) 2011-06-15

Family

ID=28041930

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03716588T ATE510534T1 (de) 2002-03-14 2003-03-14 Naltrexonhydrochlorid-zusammensetzungen

Country Status (15)

Country Link
US (2) US20030229111A1 (de)
EP (2) EP1482912B1 (de)
JP (2) JP4683842B2 (de)
KR (1) KR20040098660A (de)
CN (1) CN1652752A (de)
AT (1) ATE510534T1 (de)
AU (1) AU2003220290B2 (de)
BR (1) BR0308452A (de)
CA (2) CA2478558C (de)
CO (1) CO5611137A2 (de)
ES (1) ES2616981T3 (de)
IL (1) IL163911A0 (de)
MX (1) MXPA04008772A (de)
RU (1) RU2004130441A (de)
WO (1) WO2003077867A2 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE323491T1 (de) 1997-12-22 2006-05-15 Euro Celtique Sa Peroral zu verabreichende arzneiform enthaltend eine kombination von einem opioid agonisten und naltrexon
ES2539904T3 (es) 2000-02-08 2015-07-07 Euro-Celtique S.A. Formulaciones orales de agonistas opioides resistentes a manipulaciones indebidas
DE60238756D1 (de) 2001-05-11 2011-02-10 Endo Pharmaceuticals Inc Opioid enthaltende arzneiform gegen missbrauch
EP2316428A1 (de) 2002-04-05 2011-05-04 Euro-Celtique S.A. Matrix für die modifizierte Freigabe von aktiven Substanzen
EP1894562B1 (de) * 2002-08-15 2010-12-15 Euro-Celtique S.A. Pharmazeutische Zusammensetzungen enthaltend einen Opioidantagonisten
ES2528669T3 (es) † 2003-04-08 2015-02-11 Progenics Pharmaceuticals, Inc. Formulaciones farmacéuticas que contienen metilnaltrexona
TWI347201B (en) * 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
JP4758897B2 (ja) * 2003-09-25 2011-08-31 ユーロ−セルティーク エス．エイ． ヒドロコドンとナルトレキソンとの併用医薬
CN1938004B (zh) * 2004-03-30 2011-12-21 欧洲凯尔特公司 包含吸附剂和不利剂的抗篡改剂型
EP1604666A1 (de) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioide zur Behandlung der chronischen obstruktiven Lungenkrankheit
EP1702558A1 (de) 2005-02-28 2006-09-20 Euro-Celtique S.A. Verfahren und Vorrichtung zur Darmtätigkeitserfassung
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
WO2008015220A1 (en) 2006-08-04 2008-02-07 Ethypharm Granule and orally disintegrating tablet comprising oxycodone
TWI489984B (zh) * 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
AU2008233133B2 (en) 2007-03-29 2014-03-27 Progenics Pharmaceuticals, Inc. Crystal forms of (R) -N-methylnaltrexone bromide and uses thereof
PE20130480A1 (es) 2007-03-29 2013-05-08 Progenics Pharm Inc Compuestos heterociclicos como antagonistas del receptor opioide periferico
EP2565195B1 (de) 2007-03-29 2015-05-06 Wyeth LLC Peripherer Opioid-Rezeptor sowie Antagonisten und Verwendungen davon
WO2008133330A1 (ja) 2007-04-26 2008-11-06 Toray Industries, Inc. ４，５－エポキシモルヒナン誘導体を含有する安定な固形製剤
EP2168579B1 (de) * 2007-05-21 2017-10-11 Toray Industries, Inc. Orale zubereitung mit einer spezifischen orgnanischen säure und verfahren zur verbesserung der auflösungseigenschaft und chemischen stabilität der oralen zubereitung
EP2065038A1 (de) 2007-11-30 2009-06-03 Pharnext Neue therapeutische Ansätze zur Behandlung der Charcot-Marie-Tooth Krankheit
AU2008349873B2 (en) 2008-02-06 2014-02-13 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2'-bis-methylnaltrexone
US20110250278A1 (en) * 2008-07-01 2011-10-13 University Of Chicago Particles containing an opioid receptor antagonist and methods of use
CN101658489B (zh) * 2008-08-27 2011-11-23 海南四环心脑血管药物研究院有限公司 一种盐酸纳美芬注射液及其制备方法
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
CA2740476C (en) 2008-10-24 2016-04-05 Toray Industries, Inc. Stable tablet containing 4,5-epoxymorphinan derivative
WO2010103039A1 (en) 2009-03-10 2010-09-16 Euro-Celtique S.A. Immediate release pharmaceutical compositions comprising oxycodone and naloxone
EP2263665A1 (de) 2009-06-02 2010-12-22 Pharnext Neue Zusammensetzungen zur Behandlung von CMT und verwandten Erkrankungen
US9393241B2 (en) 2009-06-02 2016-07-19 Pharnext Compositions for treating CMT and related disorders
WO2011052499A1 (ja) * 2009-10-28 2011-05-05 第一三共株式会社 貯蔵安定性が改善された医薬組成物
TWI589293B (zh) 2010-03-11 2017-07-01 惠氏有限責任公司 甲基拿淬松（ｍｅｔｈｙｌｎａｌｔｒｅｘｏｎｅ）之口服製劑及親脂性鹽
EP2568968B1 (de) 2010-05-10 2017-07-12 Euro-Celtique S.A. Herstellung von Wirkstoff-freiem Granulat und dieses enthaltende Tabletten
JP5840201B2 (ja) 2010-05-10 2016-01-06 ユーロ−セルティーク エス．エイ． 活性剤を負荷した顆粒と追加の活性剤の組合せ
TWI560170B (en) * 2011-12-06 2016-12-01 Lundbeck & Co As H Process for recovery of nalmefene hydrochloride
CA2795324C (en) * 2012-11-09 2015-07-14 Purdue Pharma Pharmaceutical compositions comprising hydromorphone and naloxone
HUE040023T2 (hu) 2013-06-05 2019-02-28 Pharnext Stabil orális oldatok kombinált API-hoz
CA2918004C (en) 2013-07-23 2018-11-20 Euro-Celtique S.A. A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
JP6232135B2 (ja) 2013-11-13 2017-11-15 ユーロ−セルティーク エス．エイ． 疼痛およびオピオイドによる腸機能障害症候群の治療のためのヒドロモルホンおよびナロキソン
CN105582011A (zh) * 2014-10-24 2016-05-18 江苏国丹生物制药有限公司 溴甲纳曲酮固体组合物及其制备方法
EP3352823B1 (de) 2015-09-24 2021-04-21 Pain Therapeutics, Inc. Kristalline salze von naloxon und naltrexon
US10383870B2 (en) 2016-06-10 2019-08-20 Pharnext Early treatment of CMT disease
KR20190084262A (ko) * 2016-10-18 2019-07-16 앤테이아 인코포레이티드 노르-오피오이드 및 날-오피오이드 벤질이소퀴놀린 알칼로이드를 생산하는 방법
US11185540B2 (en) * 2017-04-12 2021-11-30 Pardon My Scotch Llc. Extended release compositions of opioid antagonists and phosphodiesterase 5 inhibitors
WO2020012248A1 (en) 2018-07-13 2020-01-16 Alkermes Pharma Ireland Limited Novel naphthylenyl compounds for long-acting injectable compositions and related methods
US10807995B2 (en) 2018-07-13 2020-10-20 Alkermes Pharma Ireland Limited Thienothiophene compounds for long-acting injectable compositions and related methods
US10975099B2 (en) 2018-11-05 2021-04-13 Alkermes Pharma Ireland Limited Thiophene compounds for long-acting injectable compositions and related methods
BR112022000218A2 (pt) 2019-07-10 2022-02-22 Intas Pharmaceuticals Ltd Composição farmacêutica estável livre de lactose e processo para a preparação de uma composição farmacêutica estável livre de lactose
JPWO2021100728A1 (de) * 2019-11-20 2021-05-27
EP4039252A1 (de) * 2021-02-09 2022-08-10 Sanovel Ilac Sanayi Ve Ticaret A.S. Filmbeschichtete tablette mit naltrexon-hydrochlorid

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3332950A (en) 1963-03-23 1967-07-25 Endo Lab 14-hydroxydihydronormorphinone derivatives
US4587118A (en) * 1981-07-15 1986-05-06 Key Pharmaceuticals, Inc. Dry sustained release theophylline oral formulation
FR2609632B1 (fr) * 1987-01-21 1991-03-29 Shelly Marc Nouvelle application therapeutique de la 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinon-6-one et les compositions pharmaceutiques destinees a cet usage
US4816586A (en) * 1987-07-29 1989-03-28 Regents Of The University Of Minnesota Delta opioid receptor antagonists
US5994392A (en) * 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
AU2571092A (en) * 1991-09-27 1993-04-27 Fujisawa Pharmaceutical Co., Ltd. Long-acting preparation
US6271239B1 (en) * 1992-04-13 2001-08-07 Regents Of The University Of Minnesota Delta opioid receptor-selective benzylidene-substituted morphinans
US5512578A (en) 1992-09-21 1996-04-30 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists
US5472943A (en) 1992-09-21 1995-12-05 Albert Einstein College Of Medicine Of Yeshiva University, Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists
US5580876A (en) 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5697282A (en) * 1994-03-15 1997-12-16 Schuller International, Inc. Apparatus for and method of forming large diameter duct with liner and the product formed thereby
PT914097E (pt) * 1996-03-12 2002-06-28 Alza Corp Composicao e forma de dosagem compreendendo antagonista de opioide
SK282549B6 (sk) 1997-02-14 2002-10-08 G�decke Aktiengesellschaft Spôsob stabilizácie naloxonhydrochloridu
US5980882A (en) * 1997-04-16 1999-11-09 Medeva Pharmaceuticals Manufacturing Drug-resin complexes stabilized by chelating agents
ATE323491T1 (de) 1997-12-22 2006-05-15 Euro Celtique Sa Peroral zu verabreichende arzneiform enthaltend eine kombination von einem opioid agonisten und naltrexon
US6166211A (en) * 1999-03-19 2000-12-26 Endo Pharmaceuticals, Inc. Sequential benzylic oxidations of the naloxone ring system
GB9908921D0 (en) * 1999-04-19 1999-06-16 Britannia Pharmaceuticals Ltd Spray dispenser for opiod antagonists
US6071918A (en) * 1999-07-21 2000-06-06 Dupont Pharmaceuticals Company Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
ES2539904T3 (es) * 2000-02-08 2015-07-07 Euro-Celtique S.A. Formulaciones orales de agonistas opioides resistentes a manipulaciones indebidas
WO2001085257A2 (en) * 2000-05-05 2001-11-15 Pain Therapeutics, Inc. Opioid antagonist compositions and dosage forms
DE60232417D1 (de) * 2001-08-06 2009-07-02 Euro Celtique Sa Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist
US7332182B2 (en) * 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
TWI347201B (en) * 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same

Also Published As

Publication number Publication date
KR20040098660A (ko) 2004-11-20
JP2005531515A (ja) 2005-10-20
US20170100337A1 (en) 2017-04-13
EP1482912A2 (de) 2004-12-08
AU2003220290B2 (en) 2007-06-14
CA2748620C (en) 2014-03-11
EP1482912A4 (de) 2006-11-15
EP2289492A3 (de) 2011-12-21
CA2478558C (en) 2012-09-11
JP2009143948A (ja) 2009-07-02
CO5611137A2 (es) 2006-02-28
RU2004130441A (ru) 2005-05-20
CN1652752A (zh) 2005-08-10
IL163911A0 (en) 2005-12-18
EP1482912B1 (de) 2011-05-25
CA2748620A1 (en) 2003-09-25
WO2003077867A3 (en) 2004-09-02
CA2478558A1 (en) 2003-09-25
JP5291483B2 (ja) 2013-09-18
AU2003220290A1 (en) 2003-09-29
US20030229111A1 (en) 2003-12-11
WO2003077867A2 (en) 2003-09-25
EP2289492A2 (de) 2011-03-02
MXPA04008772A (es) 2004-12-06
ES2616981T3 (es) 2017-06-15
EP2289492B1 (de) 2016-12-07
JP4683842B2 (ja) 2011-05-18
BR0308452A (pt) 2006-06-06

Similar Documents

Publication Publication Date Title
ATE510534T1 (de) Naltrexonhydrochlorid-zusammensetzungen
DE60315368D1 (de) Korrektur des Weissabgleichs
FR2838446B1 (fr) Melanges de stabilisants
DE60215179D1 (de) Dolastatin 10 derivate
IS7806A (is) Ónæmisvaldandi samsetning
DE60200746D1 (de) Kautschukzusammensetzung
DE60318890D1 (de) Mandelsäure derivate
CY1105386T1 (el) Βενζοϋλοσουλφοναμιδια και σουλφονυλβενζαμιδινες για χρηση σαν παραγοντες κατα του ογκου
DE50307455D1 (de) Einstellsystem
NO20050132D0 (no) Vaksinesammensetning
FI20010780A0 (fi) Parannetut koostumukset
DE10393374D2 (de) Zusammensetzung
DE60335716D1 (de) Beschleuniger-zusammensetzung
SE0500163L (sv) Sammansättning
DE10290365T1 (de) Gummizusammensetzung
DE60212442D1 (de) Kautschukzusammensetzung
DE50302630D1 (de) Verstellantrieb
DE10238843B8 (de) Halbleiterbauelement
DE60237109D1 (de) Rbesserte transistoreigenschaften
DE60129749D1 (de) Kautschukzusammensetzung
ITMI20022022A1 (it) Analoghi di nocicettina.
DE60326190D1 (de) des Körpers
DE60236587D1 (de) Latexzusammensetzung
NO20020524D0 (no) Stabiliserte organisk-peroksid sammensetninger
FR2843451B1 (fr) Fronde du type lance-pierres

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties